Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898211 | 0.87 | TRPV3 (0.51) | TRPV3PRMT5HPGDSALOX5APFEN1 | |
| SCHEMBL15939961 | 0.87 | GPR119 (0.50) | TRPV3PRMT5GPR119DDB1CRBN | |
| SCHEMBL9962296 | 0.83 | TRPV3 (0.53) | TRPV3PRMT5HPGDSALOX5APFEN1 | |
| SCHEMBL1428081 | 0.81 | UCHL1 (0.46) | ALOX5APFEN1MEN1ALDH1A1KMT2A | |
| SCHEMBL17672428 | 0.81 | TRPV3 (0.49) | TRPV3HPGDSGPR119MEN1KMT2A | |
| SCHEMBL30919809 | 0.80 | GPR119 (0.55) | TRPV3PRMT5HPGDSJAK2JAK1 | |
| SCHEMBL4003240 | 0.80 | GPR119 (0.55) | TRPV3PRMT5HPGDSJAK2JAK1 | |
| SCHEMBL25363244 | 0.80 | TRPV3 (0.51) | TRPV3PRMT5HPGDSALOX5APFEN1 | |
| SCHEMBL31208013 | 0.80 | TRPV3 (0.51) | TRPV3PRMT5HPGDSALOX5APFEN1 | |
| SCHEMBL26024707 | 0.80 | TRPV3 (0.51) | TRPV3PRMT5HPGDSALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | TRPV3 1521/4885PRMT5 2271/4885HPGDS 13/4885 |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | TRPV3 1521/4885PRMT5 2271/4885HPGDS 13/4885 |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | TRPV3 1521/4885PRMT5 2271/4885HPGDS 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.